Inhibitory effects of nitrendipine on myometrial and vascular smooth muscle in human pregnant uterus and placenta.
Human myometrial visceral and vascular preparations and placental chorionic and stem villous vessels were dissected from myometrial and placental specimens obtained at term Caesarean section and after vaginal delivery. Vascular ring preparations and myometrial strips were mounted in organ bath and isometric tension recorded. Only myometrial preparations developed spontaneous contractile activity, which was effectively blocked by the calcium channel blocker nitrendipine (NTD) 10(-7) M. Pretreatment with calcium-depleted medium for 30 min. almost abolished myometrial responses to high K+ (124 mmol), oxytocin (OX) and prostaglandin F2 alpha (PGF2 alpha). Vascular responses to high K+ (124 mmol) were also nearly abolished by such treatment. However, noradrenaline (NA), vasopressin (VP) and PGF2 alpha in myometrial arteries and PGF2 alpha in chorionic vessels and stem villous arteries induced significant, but reduced contractions after calcium depletion. In all vascular preparations, exposed to calcium-depleted medium, NTD (10(-8) M) almost abolished contractions induced by calcium (0.1-4.0 mM) in the presence of K+ (124 mmol) and depressed responses to calcium in the presence of the other agonists tested. NTD (10(-10)-10(-7) M) depressed myometrial contractions induced by K+, OX and PGF2 alpha more effective than vascular responses to K+, NA, VP and PGF2 alpha in the myometrial arteries and K+ and PGF2 alpha in the placental arteries. It is concluded that activation of contraction in vessels from the human utero-placental unit implies multiple cellular sources of calcium, while in myometrial smooth muscle, influx of superficially bound calcium may be an important initial step in contractile activation. Treatment with calcium channel blockers during late human pregnancy might involve relaxation of the myometrium together with vasodilatation of the myometrial and foetal placental vascular beds.
Maigaard
S
S
Forman
A
A
Brogaard-Hansen
K P
KP
Andersson
K E
KE
D002118:Calcium / Q000494:pharmacology; D015237:Dinoprost; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D009215:Myometrium / Q000098:blood supply / Q000187:drug effects; D009568:Nitrendipine / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D010920:Placenta / Q000098:blood supply / Q000187:drug effects*; D011188:Potassium / Q000494:pharmacology; D011247:Pregnancy; D011460:Prostaglandins F / Q000494:pharmacology; D014590:Uterine Contraction / Q000187:drug effects*; D014667:Vasopressins / Q000494:pharmacology
D011460:Prostaglandins F; D014667:Vasopressins; D009568:Nitrendipine; D015237:Dinoprost; D011188:Potassium; D002118:Calcium; D009638:Norepinephrine